|   Healthcare  

|   Location: Sydney, AU

Paul is a Founding Partner of OneVentures, leading the Healthcare and Biotechnology practice. He serves as Fund Lead and Chair of the Investment Committee for Healthcare Fund III and is a voting member of the Investment Committees for Funds I, II, III and V.

With over 30 years of experience in biomedical innovation, Paul provides strategic guidance to portfolio companies. He is Chair of Vaxxas and a Non-Executive Director for BiVACOR and Prota Therapeutics. Previously, he served on the boards of Hatchtech (Chair, licensed to NYSE: DRL), CharmHealth (acquired by ASX: CGL), Clinical Genomics (Enterix acquired by 3TM), Blade and Find Me.

As co-founder of Gemini Genomics (Nasdaq: GMNI), he led one of the UK’s largest biotech IPOs (US$250M valuation) before its merger with Sequenom (Nasdaq: SQNM). Earlier in his career, he co-founded Agamatrix, a bio-sensing medical device company operating in the US and Southeast Asia as well as Atomera (Nasdaq: ATMR). As CEO of Orchid Cellmark (Nasdaq: ORCH), he drove a tenfold valuation increase and significant revenue growth.

Paul began his career as a researcher and endocrinologist at St Vincent’s Hospital Sydney before transitioning into biotechnology. In the US, he held executive roles in leading biotech and medical companies driving the growth of several industry leaders.

He has authored over 100 publications in leading journals and is a Non-Executive Director at the Garvan Institute of Medical Research, a member of the UNSW Medicine Dean’s Advisory Group and serves on the Advisory Board of the Australian Government’s Australia’s Economic Accelerator (AEA) program.

Paul holds medical degrees from UNSW and is a Fellow of the Royal Australasian College of Physicians.

|   MBBS(Hons), MD, FRACP 

|   Location: Brisbane, AU

Anne-Marie is a Co-Founder of OneVentures and serves as a Director on the OneVentures Board, Responsible Manager and member of the Risk Committee. She is a voting member of the Investment Committees for Funds I, II and III.

She is a Director for OneVentures portfolio company Madorra and previously chaired the CharmHealth board, leading its acquisition by the Citadel Group in 2017 (ASX: CGL).

With 25 years in product development and commercialisation and 15 years in funds management, Anne-Marie has held significant leadership roles, including CEO of i.lab Incubator and General Manager Operations at UniQuest. She is deeply engaged with industry, universities and government, fostering scientific innovation and commercial success.

A champion for diversity, she co-founded Women in Biotechnology (which later merged into Women in Technology), served on the board of Springboard Enterprises and mentors entrepreneurs, scientists and emerging leaders in venture capital.

Anne-Marie is a Director for InterFinancial, ASX-listed PPK Group (ASX: PPK) and UniQuest. She chairs the Project Investment Committee and is a member of the Industry Steering Committee for the University of Queensland-led Trailblazer Food and Beverage Accelerator.

Holding a Bachelor of Science (Hons), an MBA and PS146 accreditation, she is a member of the Australian Institute of Company Directors (MAICD), a Registered Technology Transfer Professional (RTTP) and a Fellow of the Australian Academy of Technological Sciences and Engineering (FTSE).

|   BSc(Hons), MBA, GAICD 

|   Healthcare

|   Location: Brisbane, AU

Sarah is a Partner at OneVentures, focused on sourcing and supporting life sciences companies developing transformative technologies with global potential.

She currently serves as Chair of Axial Therapeutics, a Board Member for Kira Biotech and an Alternate Board Member and Observer for Vaxxas, Clinical Genomics and Prota Therapeutics.

Sarah brings over 20 years of enterprise-level leadership experience across the life sciences ecosystem, from agriculture to healthcare. Her career spans start-ups, private and public companies (ASX- and NASDAQ-listed), multinational pharma, and university research organisations. She has a strong track record in deal-making, from early-stage investments and university collaborations to major pharma transactions worth hundreds of millions of dollars.

Prior to joining OneVentures, Sarah held roles in business development and commercial strategy in Australia and the United States, combining deep scientific expertise with commercial acumen to drive innovation to market.

Sarah holds a Bachelor of Agricultural Science with First Class Honours from the University of Queensland and a Master’s in Genomics from Cornell University. She has post-graduate training in negotiation from Harvard and is a Graduate of the Australian Institute of Company Directors (GAICD). She is also a member of the QIMR Berghofer Medical Research Institute Commercial Advisory Board and the AusBiotech Investment Advisory Group.

|   BAgrSc(Hons), M.P.S, GAICD

|   Healthcare

|   Location: Melbourne, AU

Jeannie is a Venture Partner at OneVentures, supporting healthcare portfolio company operations and strategic initiatives.

She serves on the board of ImmVirX (deal lead), BiVACOR Pty Ltd, BiVACOR Australia and Hatchtech, and has previously held board roles with BiVACOR Inc (as Chair and Director).

A biopharmaceutical and medical device leader with 20+ years of global experience, Jeannie has held senior executive and advisory roles in Australia and the US. Her expertise includes business development, strategic partnerships, and operational leadership across research, clinical trials, and commercial management.

In the US, she led global business development, licensing medical device technologies to major pharmaceutical companies and securing milestone and royalty payments. Her career includes roles with organisations such as Bristol-Myers Squibb, Mayne Pharma, CSL, and Enable Injections.

Jeannie holds a PhD and a Bachelor of Science (Hons) in Immunology from Monash University and a Diploma of Marketing from the Melbourne Business School. She currently serves as a Non-Executive Director for ASX-NASDAQ listed Immuron and ASX-listed Argenica.

|   BSc(Hons), PhD   

|   Healthcare  

|   Location: Sydney, AU

John is a Venture Partner at OneVentures supporting the Healthcare team and portfolio companies with strategic guidance and operational expertise.

He has over 20 years of global experience in life sciences spanning operational leadership, venture capital and investment banking.

Previously, John was CFO of Elastagen, an Australian medical device company, where he led fundraising. He also played a key role in the international expansion of the company’s clinical studies in the UK and in the company’s acquisition by Allergan. Elastagen was recognised as the Australian Investment Council’s Best Venture Capital Investment of 2018. Post-acquisition he oversaw the integration of Elastagen’s clinical programs as Director of R&D and later as a consultant.

Prior to his tenure at Elastagen, John spent eight years at Nomura Phase4 Ventures in London investing in early to mid-stage life science companies across the US and Europe. He began his career at Morgan Stanley advising healthcare multinationals on capital raising, divestitures and acquisitions.

John holds a PhD and a BSc (Hons) in Biochemistry from Heriot-Watt University, completing the first year of his PhD at Dundee University. He is a recipient of the Watt Club Medal.

|   BSc(Hons), PhD

|  Healthcare 

|  Location: Sydney, AU

|   Healthcare

|   Location: Sydney, AU

Lu focuses on healthcare investments, supporting the team with deal sourcing and screening, due diligence and investment monitoring.

She draws on her expertise in equity research and biomedical sciences to inform investment decisions and drive deal-term negotiations.

Before joining OneVentures, Lu interned as Biotech Equity Research analyst at CITIC Securities and worked as a scientific writer and technical consultant at DeepTech, covering biotech startups and advancements in biomedical research. She brings over seven years of academic research experience in biomedical sciences with a strong technical background in R&D.

Lu holds a Ph.D. in Pathobiology from the University of Connecticut where her research focused on infectious disease pathogenesis. She has completed Level 2 of the CFA program.

|   PhD, Pathobiology